

be the most effective in achieving seizure freedom. The study of temporal lobe epilepsy for surgical treatment is extensive and complex. It involves a multidisciplinary team in decision-making with initial non-invasive studies (Phase I), providing 70% of required information to elaborate a hypothesis and treatment plans. Select cases present more complexity involving bilateral clinical or electrographic manifestations, have contradicting information or may involve deeper structures as a part of the epileptogenic zone. Methods: A review of the literature was done with key terms such as: “temporal lobe epilepsy” and “SEEG” and “intracranial EEG”, “epilepsy surgery”, un Pubmed, EMBASE, Medlink and Scielo. Most cutting edge, controversial subjects surrounding this field were considered. Results: In this comprehensive review, we explore the indications, usefulness, discoveries in interictal and ictal findings, pitfalls, and advances in the science of presurgical stereo-encephalography for temporal lobe epilepsy. Conclusions: Intracranial recording follows original concepts since its development by Bancaud and Talairach, but great advances have been made in the field. Stereo-electroencephalography is a growing field of study, treatment and establishment of seizure pattern complexities.

P.014

Immunotherapy responses of patients with suspected autoimmune-associated epilepsy with negative neural antibody testing

N ALKhalidi (London)* *A Budhram* (London) *J Burneo* (London) *S Mirsattari* (London) *M Jones* (London), *A Suller-Marti* (London)

doi: 10.1017/cjn.2022.117

Background: In refractory epilepsy patients with possible autoimmune-associated epilepsy (AAE) but negative antibody testing (-AB), immunotherapy trials (IMT) may still be pursued. The value of (IMT) in such patients remains unclear. For this reason, we reviewed their immunotherapy responses. Methods: Retrospective review of epilepsy patients admitted to the Epilepsy Unit between (2018-2021) who received (IMT). All had (-AB) and received immunotherapy (methylprednisolone (IVMP)-immune globulin (IVIg)-plasma exchange (PLEX)-rituximab). We considered responders when their seizure reduction was $\geq 50\%$. Results: 14 patients identified. Of them, 50% (n=7) females. Median age (43.5 year. IQR= 28.75-63.25). All refractory to ≥ 2 anti-seizure medications (ASM). Median epilepsy onset was (39.5 years. IQR=23.75-60.25). Median time from diagnosis until received immunotherapy was (15.5 months. IQR=12.75 -21.75). Patients received either IVIG+IVMP (35.7%, n=5) or IVIG alone (28.5%, n=4) or IVIG+IVMP+PLEX (21.4%, n=3) or IVMP alone (7.1%, n=1) or IVIG+IVMP+rituximab (7.1%, n=1). Median follow-up was 25 months. Although early immunotherapy responses were common, sustained response to immunotherapy at last follow-up was only in 21.4% (n=3). Factors confounding determination of immunotherapy efficacy were present in all responders (e.g: concurrent changes in ASM). Conclusions: Our findings suggest that (IMT) in patients with suspected (AAE) but with (-AB) are largely unsuccessful. This suggests an insufficient therapeutic effect after (IMT) or alternatively, non-immune-mediated

mechanisms causing this type of epilepsy. Critical evaluations of (IMT) in such cases are needed.

HEADACHE

P.015

Monthly migraine days, acute medication use-days, and migraine-specific quality of life in responders to atogepant: a post hoc analysis

DW Dodick (Scottsdale) *RB Lipton* (Bronx) *SJ Nahas* (Philadelphia) *P Pozo-Rosich* (Barcelona) *P McAllister* (Stamford) *LL Mechtler* (Buffalo) *E Leroux* (Montreal)* *J Ma* (Madison) *B Dabruzzo* (Madison) *M Dufek* (Madison) *L Severt* (Madison) *M Finnegan* (Madison), *J Trugman* (Madison)

doi: 10.1017/cjn.2022.118

Background: In phase 3 ADVANCE, atogepant 60mg reduced mean monthly migraine days (MMDs) from 7.8 days (baseline) to 3.0 (weeks 9-12; $\Delta=-4.7$) in the overall episodic migraine population [treatment responders and nonresponders (i.e., marked benefit and minimal benefit)], which obscures information regarding magnitude of treatment effect in these populations. Here, magnitude of treatment effect in atogepant responders and nonresponders is characterized. Methods: Mean MMDs, acute medication use-days (MUDs), and Migraine-Specific Quality of Life-Role Function-Restrictive (MSQ-RFR) scores were calculated in treatment responders (based on MMD percentage reduction) and nonresponders from ADVANCE participants. Results: From baseline to weeks 9-12, $\geq 50\%$ improvement was achieved by 71% (139/195) of participants. In these responders, MMDs reduced from 7.6 to 1.3 ($\Delta=-6.3$). 50% (97/195) of participants achieved $\geq 75\%$ response. In this group, MMDs reduced from 7.7 to 0.6 ($\Delta=-7.1$). Atogepant 60mg nonresponders ($<25\%$ reduction in MMDs; 15% [30/195 participants]) showed MMD change from 7.7 to 9.1 ($\Delta=+1.4$). Acute MUDs in $\geq 50\%$ MMD responders decreased 7.1 to 1.6 ($\Delta=-5.5$). In treatment-nonresponders, acute MUDs were 7.3 (baseline) and 7.2 (weeks 9-12; $\Delta=-0.1$). Similar mean MSQ-RFR score changes were observed in both populations. Conclusions: Of participants who experienced $\geq 50\%$ reduction in MMDs, 71% had substantial treatment effect ($\Delta\text{MMD}=-6.3$), representing 83% reduction in MMDs.

P.016

Reduction in migraine-associated burden over 24 weeks of treatment with eptinezumab in patients with chronic migraine

P McAllister (Stamford) *D Kudrow* (Santa Monica) *R Cady* (Deerfield) *J Hirman* (Woodinville) *A Ettrup* (Copenhagen), *S Minhas* (Montreal)*

doi: 10.1017/cjn.2022.119

Background: To examine changes in the occurrence, severity, and symptoms of headache episodes in patients with chronic